secwatch.observer — SEC 8-K summary
======================================

Issuer:     Elanco Animal Health Inc (ELAN)
CIK:        0001739104
Form:       8-K/A
Filed at:   2023-03-01T23:59:59+00:00
Accession:  0001104659-23-027183
Event type: other_material
Sentiment:  negative
Materiality: 0.40
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Elanco revises Q4/FY2022 results for immaterial errors; reports material weakness in internal controls
--------------------------------------------------------------------------------

- Q4 2022 revenue revised down $3M to $985M; reported net loss increased to $55M; adjusted EBITDA $172M (down $2M).
- Full year 2022 revenue revised down $7M to $4,411M; reported net loss $78M (up $4M); adjusted EBITDA $1,017M (down $6M).
- Reported EPS unchanged at $(0.11) for Q4; full year reported EPS revised to $(0.16) from $(0.15); adjusted EPS unchanged.
- Net leverage increased to 5.5x from 5.4x; no impact on 2023 guidance.
- Material weakness in internal control over financial reporting related to income tax provisions identified in 10-K.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1739104/000110465923027183/0001104659-23-027183-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1739104/000110465923027183/tm238102d1_8ka.htm
  HTML page:      https://secwatch.observer/filing/0001104659-23-027183

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer